2026 ICD-10-CM Diagnosis Code T80.52XSAnaphylactic reaction due to vaccination, sequela

ICD-10-CM Codes›S00–T88›T80-T88›T80

ICD-10-CM T80.52XS
CMSSource: CMS FY 2026 ICD-10-CM dataset · Effective Oct 1, 2025 – Sep 30, 2026

T80.52XS is a billable ICD-10-CM diagnosis code for anaphylactic reaction due to vaccination, sequela. The 7th character S marks it as a sequela code, which reports a problem that remains after the original condition has resolved. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 922 through 923. The code is exempt from POA reporting. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Complication, sequela.

Code Identity

ICD-10-CM Code
T80.52XS
Billable Status
Yes — Valid for Submission
Code Describes
Anaphylactic reaction due to vaccination, sequela
Short Description
Anaphylactic reaction due to vaccination, sequela
Same as the full description in the CMS dataset.
Parent Code
T80.52
Anaphylactic reaction due to vaccination

Code Classification

ChapterS00–T88Injury, poisoning and certain other consequences of external causes
SectionT80-T88Complications of surgical and medical care, not elsewhere classified
CategoryT80Complications following infusion, transfusion and therapeutic injection
This CodeT80.52XSAnaphylactic reaction due to vaccination, sequela

Present on Admission (POA)Billing

T80.52XS is exempt from POA reporting on inpatient claims to general acute care hospitals. Review other POA exempt codes.

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Adverse reaction to component of vaccine product containing low dose acellular Bordetella pertussis and Clostridium tetani and low dose Corynebacterium diphtheriae antigens
  • Adverse reaction to component of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens
  • Adverse reaction to component of vaccine product containing only live attenuated Human alphaherpesvirus 3 antigen
  • Adverse reaction to component of Vaccine product containing Rotavirus antigen
  • Adverse reaction to Haemophilus influenzae type b vaccine
  • Adverse reaction to hepatitis A vaccine
  • Adverse reaction to hepatitis B vaccine
  • Adverse reaction to Human papillomavirus vaccine
  • Adverse reaction to influenza virus vaccine
  • Adverse reaction to measles vaccine
  • Adverse reaction to meningococcal vaccine
  • Adverse reaction to mumps vaccine
  • Adverse reaction to pertussis vaccine
  • Adverse reaction to pneumococcal vaccine
  • Adverse reaction to poliomyelitis vaccine
  • Adverse reaction to rubella vaccine
  • Adverse reaction to Varicella-zoster virus vaccine
  • Anaphylaxis caused by component of vaccine product
  • Anaphylaxis caused by component of vaccine product against severe acute respiratory syndrome coronavirus 2
  • Anaphylaxis caused by component of vaccine product containing low dose acellular Bordetella pertussis and Clostridium tetani and low dose Corynebacterium diphtheriae antigens
  • Anaphylaxis caused by component of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens
  • Anaphylaxis caused by rotavirus vaccine
  • Anaphylaxis caused by vaccine containing Human alphaherpesvirus 3 antigen
  • Anaphylaxis caused by vaccine product containing Hepatitis A virus antigen
  • Anaphylaxis caused by vaccine product containing Hepatitis B virus antigen
  • Anaphylaxis caused by vaccine product containing human alphaherpesvirus 3 recombinant surface glycoprotein E antigen
  • Anaphylaxis caused by vaccine product containing Human papillomavirus antigen
  • Anaphylaxis caused by vaccine product containing human poliovirus antigen
  • Anaphylaxis caused by vaccine product containing Influenza virus antigen
  • Anaphylaxis caused by vaccine product containing live attenuated human alphaherpesvirus 3 antigen
  • Anaphylaxis caused by vaccine product containing Measles morbillivirus and Mumps orthorubulavirus and Rubella virus antigens
  • Anaphylaxis caused by vaccine product containing only Clostridium tetani and Corynebacterium diphtheriae antigens
  • Anaphylaxis caused by vaccine product containing only Haemophilus influenzae type b antigen
  • Anaphylaxis caused by vaccine product containing only Neisseria meningitidis antigen
  • Anaphylaxis caused by vaccine product containing Streptococcus pneumoniae antigen

Coding GuidelinesGuidance

The appropriate 7th character is to be added to each code from block Complications following infusion, transfusion and therapeutic injection (T80). Use the following options for the applicable episode of care:

  • A - initial encounter
  • D - subsequent encounter
  • S - sequela

Source: ICD-10-CM Official Guidelines for Coding and Reporting, FY 2026, published by CMS and the National Center for Health Statistics.

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR INJ076
Complication, sequela
Default principal diagnosis: inpatient Yes · outpatient Yes

Patient EducationClinical

Anaphylaxis

Anaphylaxis is a serious allergic reaction. It can begin very quickly, and symptoms may be life-threatening. The most common causes are reactions to foods (especially peanuts), medications, and stinging insects. Other causes include exercise and exposure to latex. Sometimes no cause can be found.

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert T80.52XS to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
909.3 Late eff surg/med compl
Approximate The match is approximate rather than exact.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2025No changes
FY 2026CurrentCurrent code set, no changesEffective October 1, 2025 through September 30, 2026.

Questions About T80.52XSOverview

Is T80.52XS (Anaphylactic reaction due to vaccination) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report anaphylactic reaction due to vaccination, sequela on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

What does the 7th character S in T80.52XS mean?

The final character S makes this a sequela code: it reports a lingering problem that remains after the anaphylactic reaction due to vaccination itself has resolved, not the original event.

What MS-DRG does T80.52XS group to?

When anaphylactic reaction due to vaccination, sequela is the principal diagnosis on an inpatient stay, it groups to MS-DRG 922, 923, with relative weights from 1.0177 to 1.7494 depending on complications. Higher weights mean higher Medicare reimbursement.

Is T80.52XS exempt from POA reporting?

Yes. CMS lists this code among those exempt from present on admission reporting, so hospitals do not assign a POA indicator for anaphylactic reaction due to vaccination, sequela on inpatient claims.

What is the ICD-9 equivalent of T80.52XS?

Under the General Equivalence Mappings, anaphylactic reaction due to vaccination, sequela converts to ICD-9-CM 909.3 (late eff surg/med compl). The mapping is approximate, so confirm the match fits the documentation.

Footnotes

[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.